Injectable forms under contract to the world

Instituto Biológico Contemporáneo S.A. (IBC) is a company of Argentine capital exclusively dedicated to the elaboration of injectable medicinal specialties for the national and international pharmaceutical industry.


Pharmavial Hospital Line

Laboratorio IBC has its own line of products for hospital use PHARMAVIAL, direct production and marketing. PHARMAVIAL offers the market a guaranteed quality alternative with a varied portfolio of products in lyophilized pharmaceutical forms, injectable liquid solutions and sterile powders.

Filter by:

{{ product.name }}

Active Ingredients: {{ product.active_principle }}

Presentación: {{ product.presentation }}

Unit per box: {{ product.units_per_box }}

Therapeutic line: {{ product.therapeutic_line }}


There are no products to display


About us

Instituto Biológico Contemporáneo S.A. (IBC) is an Argentine-owned company dedicated exclusively to the production of injectable medical specialties, for both the national and the international pharmaceutical industry.

Since its establishment in the Autonomous City of Buenos Aires in 1989, IBC has developed a policy based on growth and continuous improvement. A milestone on its trajectory is the launch of the PHARMAVIAL line, initiating a new impulse of growth and expansion.

From its beginnings, IBC has had a constant vocation to provide quality excellence in all its pharmaceutical services. This is supported by a highly trained team of professionals, modern facilities, and state-of-the-art technology. Our structure guarantees the compliance with the strict standards of GMP (Good Manufacture Practices) and GLP (Good Laboratory Practices), that govern the pharmaceutical industry.

Apart from the local certifications of ANMAT, we are also certified by MERCOSUR and INVIMA (Colombia), which has allowed IBC to gain access to the international market in Latin America and Asia, since 2018.

Our development team works on the creation of new products and the expansion of the portfolio, with the strong determination of evolving and growing constantly.

slide institucional

Production plant

The plant has a module dedicated exclusively to the production of injectables with general active ingredients in lyophilized injectable pharmaceutical forms and solution in a covered area of ​​2,900 m2. For this, it has two 150-liter capacity freeze-drying equipment with productions between 7,000 and 26,000 units, two new 300-liter freeze-drying equipment for the manufacture of between 20,000 and 65,000 units and a modern dosing equipment for injectable solutions with capacities between 4,000 and 18,000 units hours. The latter two are equipped with a continuous production line with a washing / depyrogenating / dosing tunnel for bottles and ampoules that ensure the aseptic quality of the product at high production levels.

The plant for the preparation of sterile and lyophilized injectable solutions have areas classified according to international quality standards and state-of-the-art technological automatic equipment. The segregated plant for beta-lactam and carbapenemic antibiotics has a covered area of ​​2,000 m2 and has a continuous production line for washing / depyrogenating / dosing / checking and packaging of sterile powders that guarantee optimal production levels for a production of 10,000 units hours .

Annual production capacity

Ampoules 24 million units
Viales líquidos 50 million units
Liofilizados 10 million units



Any Pharmacovigilance situation related to medicinal specialties marketed in Argentina by Laboratorio IBC is treated by health professionals within the current national regulatory framework and in accordance with Good Pharmacovigilance Practices.

The activities for receiving notifications, referring to adverse events and other special reporting situations, are validated, documented and compiled in compliance with the current applicable regulation and the Pharmacovigilance agreements between the IBC Laboratory and its licensors.


Enter your name.
Enter a phone.
Enter a valid email.
Enter your comments.